Immunophotonics is a biotech company developing a proprietary carbohydrate polymer (N-dihydrogalactochitosan or "IP-001"). Immunophotonics’ technology is intended to be compatible with a variety of current ablation techniques for the potential treatment of a wide variety of solid tumor indications.

  • Turns a common local tumor ablation into a systemic immunotherapy for cancer, targeting both local tumors and distant metastases
  • Potential to improve outcomes of the large number of tumor ablation procedures that are occurring on an annual basis
  • Off-the-shelf drug with low COGS, simple administration and reproducible manufacturing
  • Potential synergy with recently approved cancer immunotherapies such as anti-PD-1 and anti-CTLA4
  • IP-001 is intended to be injected immediately (directly into the location of the ablated tumor) after an approved ablation
  • No laboratory or ex vivo processing required to produce desired immunotherapeutic effects
  • Favorable safety profile allowing potential development in both early and late stage cancers
  • Significant clinical unmet need and market opportunity
  • Patent protection until 2033
Limitations of Ablations

Tumor ablation involves the destruction of tumors using physical methods (heat, cold, radiation, etc) or chemical agents directly applied to the tumor. In fact, over the past 30+ years, tumor ablation has gained importance (global market >$1B in 2018), particularly in patients not eligible for surgical resection. Unfortunately, while these methods can effectively destroy targeted tumors, they also come with a significant limitation: Similar to surgery, the effects of these procedures are almost always only local, and although evidence shows that ablation may lead to production of danger signals that could support an immune response, it is usually insufficient for the complete eradication of established tumors, micrometastases or distant metastases.

IP-001 Transforms Local Tumor Ablation into Systemic Immunotherapy

IP-001 is a novel compound that is intratumorally injected after a tumor ablation, utilizing the whole repertoire of tumor associated neoantigens availabe in situ for the immune system after ablation-based immunogenic cell death. Collectively, with ablation + IP-001, a systemic antitumor response may be initiated.

Effective Across Many Ablation Techniques

IP-001 is procedure-agnostic as its efficacy has been demonstrated in preclinical models following treatment with a variety of ablation techniques including photodynamic therapy, thermal laser, and high intensity focused ultrasound.

Synergy with Existing Immunotherapies

Importantly, a prominent tumor-specific T Cell response induced by IP-001 injection can prime the patient to be more responsive to downstream immuno-oncology therapies, thus ultimately, potentially improving their clinical efficacy. This is an opportunity as many immunotherapies would benefit from higher response rates. Immunophotonics plans to conduct further studies exploring alternative options of combining IP-001 with other technologies. IP-001 may be combined with other immunotherapeutic approaches to further enhance an immune response against cancer.

Immunophotonics’ Patent Coverage To Support Library of Novel Polymers

Immunophotonics has developed a well thought-out and sophisticated offensive patent strategy, taking a multi-faceted, multi-layered approach to protecting not just the novel composition itself and the application of that novel composition as a method of treatment, but also the chemical space surrounding the novel composition. Our composition of matter patent has been issued in several countries with coverage until 2033. In addition to IP-001, our core platform technology and intellectual property will allow the continued development of additional novel carbohydrate polymers for use in the cancer immunotherapy space.